Effect of Heparin on Antigen-Antibody Interaction in a Model System of the Bevacizumab Therapeutic Antibody And its Target VEGF-А165-Reference-Cited by-同舟云学术

Effect of Heparin on Antigen-Antibody Interaction in a Model System of the Bevacizumab Therapeutic Antibody And its Target VEGF-А165

Published:2023-11-20 Issue:3E Volume:19 Page:77-80
ISSN:2713-0428
Container-title:Journal Biomed
language:
Short-container-title:BIOMEDICINE

Author:

Shevelyova M. P.¹,Nemashkalova E. L.¹,Deryusheva E. I.¹

Affiliation:

1. Institute for Biological Instrumentation of the Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences

Abstract

In this work, we studied the effect of heparin on the binding process of VEGF-A165, the most common and important growth factor, and the monoclonal antibody bevacizumab by bio-layer interferometry. A complex of the full-length bevacizumab antibody with VEGF-A165 was modeled. The data obtained can be used in therapy with this antibody, as well as in the development of other therapeutic antibodies with maximum target specificity under various conditions.

Publisher

Scientific Center for Biomedical Technologies of the Federal Medical-Biological Agency

Subject

General Medicine

Reference10 articles.

1. Adamis A.P., Shima D.T. The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005;25:111–118. DOI: 10.1097/00006982-200502000-00001.

2. Apte R.S., Chen D.S., Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176:1248–1264. DOI: 10.1016/j.cell.2019.01.021.

3. Engelberg H. Plasma heparin levels in normal man. Circulation. 1961;23:578–581. DOI: 10.1161/01.cir.23.4.578.

4. Ferrara N. VEGF-A: A critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009;20:158–163. DOI: 10.1684/ecn.2009.0170.

5. Garcia J., Hurwitz H.I., Sandler A.B., Miles D., Coleman R.L., Deurloo R., Chinot O.L. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat. Rev. 2020;86:102017. DOI: 10.1016/j.ctrv.2020.102017.